Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. The Lancet Public Health 2017;2:e149-56. [Ref.ID 101922]

Anónimo. Chutes et médicaments. Prescrire 2016;36:825. [Ref.ID 100951]

Anónimo. Diarrhées d'origine médicamenteuse. Prescrire 2016;36:748-55. [Ref.ID 100894]

Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet 2016;388:505-17. [Ref.ID 100647]

Gustafsson M, Isaksson U, Karlsson S, Sandman P-O, Lovheim H. Behavioral and psychological symptoms and psychotropic drugs among people with cognitive impairment in nursing homes in 2007 and 2013. Eur J Clin Pharmacol 2016;72:987-94. [Ref.ID 100274]

Anónimo. Donepezilo y riesgo de rabdomiólisis y de síndrome neuroléptico maligno. Butlletí de Farmacovigilància de Catalunya 2015;13:19. [Ref.ID 99837]

Roxton K, Woodman RJ, Mangoni AA. Drug with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol 2015;80:209-20. [Ref.ID 99476]

Anónimo. Donépézil: rhabdomyolyses et syndrome malins. Prescrire 2015;35:506. [Ref.ID 99438]

Villegas S. Enfermedad de Alzheimer: nuevas estrategias terapéuticas. Med Clin (Barc) 2015;145:76-83. [Ref.ID 99323]

Anónimo. Incontinences urinaires d'origine médicamenteuse. Prescrire 2015;35:271-4. [Ref.ID 99126]

Anónimo. FDA approves combo treatment for Alzheimer’s-related dementia. DIA Daily 2014:29 de diciembre. [Ref.ID 98396]

Tija J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL. Use of medications of questionable benefit in advanced dementia. JAMA Intern Med 2014;174:1763-71. [Ref.ID 98299]

Bellostas Umbert JM, Carnero Pardo DC, García Lirola MA. Enfermedad de Alzheimer: tratamiento farmacológico. Boletín Terapéutico Andaluz 2014;29:1-9. [Ref.ID 98102]

Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311:1670-83. [Ref.ID 97495]

Anónimo. Anticholinestérasiques dans la maladie d'Alzheimer: que penser de l'essai dit Domino?. Prescrire 2014;34:315-6. [Ref.ID 97444]

Anónimo. Maladie d'Alzheimer: trop de patients exposés aux interactions avec les anticholinestérasiques en France. Prescrire 2014;34:114. [Ref.ID 97128]

Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, LLorente M, Love S, Schellenberg GD, McCarten R, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnells KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD. ·Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014;311:33-44. [Ref.ID 97033]

Evans DA, Morris MC, Rajan KB. Vitamin E, memantine, and Alzheimer disease. JAMA 2014;311:29-30. [Ref.ID 97032]

Anónimo. Maladie d'Alzheimer: des patients trop exposés aux anticholinestérasiques et à la mémantine en France. Prescrire 2014;363:23. [Ref.ID 97008]

Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol 2013;69:1467-75. [Ref.ID 95853]